Breitburn Energy Partners L.P. (Nasdaq:BBEP) announced financial and operating results for its first quarter of 2011. Key Highlights: The Partnership delivered another quarter of strong financial and operating results, with EBITDA, production, and lease operating expenses trending in-line with or exceeding guidance. In February 2011, the Partnership completed a public offering of 4,945,000 common units at $21.25 per unit representing additional limited partner interests. The Partnership received net proceeds of approximately $100 million, which were used to reduce borrowings under its bank credit facility and increase the Partnership’s flexibility in funding future acquisitions. As of April 30, 2011, the Partnership had $121 million outstanding under the credit facility. On April 28, 2011, the Partnership announced an increased cash distribution for the first quarter of 2011 at the rate of $0.4175 per unit, or $1.67 on an annualized basis, to be paid on May 13, 2011 to the record holders of common units at the close of business on May 10, 2011. This represents an increase of 11.3% over the cash distribution for the first quarter of 2010.
BreitBurn Energy Partners L.P. engages in the acquisition, exploitation, and development of oil and gas properties in the United States. Its assets primarily consist of producing and non-producing crude oil and natural gas reserves located primarily in the Antrim Shale in Michigan, the Los Angeles Basin in California, the Wind River and Big Horn Basins in central Wyoming, the Sunniland Trend in Florida, and the New Albany Shale in Indiana and Kentucky.
Power3 Medical Products, Inc. (PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 Medical Products, Inc. applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical Products, Inc. has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Breast cancer is the most common type found in women that has been very fast in gulping lives. This starts with an abnormality in a mammogram, a lump, or a slight change in the breast tissues. Family history of breast cancer or any sort of cancer is said to be a convincing reason to have a risk of cancer. However, the primary reason for a breast cancer remains a hormonal or genetic change or issue.
The usual pattern of growing cells is that the cells break down and form new cells. The old or damaged cells had to die and get out of the body to make place for newer ones. But sometimes an abnormality happens and these damaged cells do not get removed or new cells get produced even when not required. These extra cells in the body get no place to settle down and so they create a lump or a tumor in a particular part of body.
Breast cancer cells can move to the connected parts after breaking away from its tumor and moving out through blood vessels or lymph. They can form new tumors this way and damage a lot more tissues.
BC-SeraPro� is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminates function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro� test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
For more information, please visit their website: http://www.power3medical.com
Staples, Inc. (Nasdaq:SPLS) will hold its quarterly conference call to discuss first quarter 2011 results on Wednesday, May 18, 2011 at 9:00 a.m. Eastern Time (8:00 a.m. Central Time). This call is being webcast by Thomson Reuters and can be accessed at Staples’ Web site at http://investor.staples.com. The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.earnings.com, Thomson Reuters’ individual investor portal. Institutional investors can access the call via StreetEvents, Thomson Reuters’ password-protected event management site, at www.streetevents.com.
Staples, Inc., together with its subsidiaries, operates as an office products company. The company sells various office supplies and services, business machines and related products, computers and related products, and office furniture.
EMC Insurance Group Inc. (Nasdaq:EMCI) reported an operating loss of $0.01 per share for the first quarter ended March 31, 2011, compared to operating income of $0.73 per share for the first quarter of 20101. Net income, including realized investment gains and losses, totaled $5,221,000 ($0.40 per share) for the first quarter of 2011 compared to $9,878,000 ($0.75 per share) for the first quarter of 2010. “First quarter 2011 is a stark reminder of our business purpose to insure our policyholders against loss. Our hearts go out to all those affected by the catastrophic events of the first quarter,” stated Bruce G. Kelley, President and Chief Executive Officer. “Both our property and casualty insurance and our reinsurance segments tallied large losses from national and world-wide events of the quarter.”
EMC Insurance Group Inc., through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through two segments, Property and Casualty Insurance, and Reinsurance.
No comments:
Post a Comment